Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
drugs
11
×
life sciences
national blog main
biotech
clinical trials
boston blog main
brexit
europe
europe blog main
falsified medicines
fda
innovation
labeling
mhra
new york blog main
news
regulations
uk
amgen
boston top stories
national
national top stories
new york
new york top stories
recall
san diego blog main
san diego top stories
achaogen
adams street partners
akcea therapeutics
alirocumab
alnylam pharmaceuticals
antibiotics
anylam pharmaceuticals
beta lactamase inhibitor
biomedical advanced research and development authority (barda)
boston
calcitonin gene-related peptide
cardiomyopathy
chronic migraine
What
medicines
11
×
drug
brexit
charting
choppy
course
dynamic
end
new
period
plans
post
products
regulation
regulatory
reveals
transition
uk
alnylam
announced
approved
based
disease
fda
pharmaceuticals
recall
year
additional
ago
akcea
amyloidosis
approval
attr
available
bacteria
battle
berlin
berlin’s
biopharma
bringing
Language
unset
unknown
Current search:
medicines
×
drugs
×
@bgr.com
2 years ago
These 2 medicines are being pulled from store shelves right now
@tech.eu
2 years ago
Berlin’s MAYD gets paid in €30 million Series A round, Lightspeed leads the parade
@bgr.com
2 years ago
New drug recall issued: Stop taking these cold & flu medicines immediately
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines